Argen X SE
Open
$879.94
Prev. Close
$879.46
High
$881.52
Low
$878.05
Market Snapshot
$53.62B
-2.70
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Recently from Cashu
Argen X SE's Vyvgart Gains Advantage Amid Competitors' Setbacks in Biotech Market
Argen X SE (Ticker: ARGX) maintains a strong position in the biotech industry, particularly following the recent challenges faced by competitors. With Sanofi SA discontinuing its Phase 3 MOBILIZE stud…
Argenx Achieves Success in Proptosis Treatment with Elegrobart Trial Results
Argenx Advances in Proptosis Treatment with Elegrobart Trial Success Argenx SE marks a significant milestone in its ongoing research and development efforts with the successful outcome of the REVEAL-1…
Argenx SE Faces Analyst Divergence Amidst Innovative Therapy Development and Market Competition
Argenx's Innovative Therapy Development Under Scrutiny Amid Analyst Divergence Argenx SE is currently at the forefront of the biotechnology sector, as its innovative therapies continue to draw the att…
Argenx SE: Balancing Innovation and Competition in the Biotech Sector
Argenx SE: Navigating a Complex Landscape of Innovation and Competition Argenx SE, a key player in the biotechnology sector, currently navigates a multifaceted landscape characterized by both innovati…